|
||||||
| Home |
| Find a Clinical Trial |
| Clinical Trial FAQs |
| About Informed Consent |
| Clinical Trials Glossary |
| Medical Research Areas |
| Clinical Trial Resources |
|
 |
Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only. | |
|
|
 |
|
|
|
|||
|
Novartis Clinical
Trials provides information about research studies recruiting
within the U.S. Visit ClinicalTrials.gov, a registry of federally and privately supported clinical trial for more information regarding clinical trials outside of the U.S. |
|
|
Find a Clinical Trial
Chronic Myelogenous Leukemia (CML)
Chronic myelogenous leukemia (CML) is a cancer of the blood and bone marrow. All blood cells are made by stem cells in the bone marrow, which is the spongy tissue inside your bones. There are 3 types of blood cells: red cells, which carry oxygen to all the tissues in the body; white cells, which fight infection; and platelets, which allow the blood to clot to help stop bleeding when a blood vessel is damaged. In CML, the stem cells in the bone marrow make too many white blood cells, some of which never mature. These immature white blood cells collect in the bone marrow and blood. Eventually, the extra white blood cells crowd out the healthy red cells and platelets and interfere with the functioning of other organs. This causes the symptoms of CML.
Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial. For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy. Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.
Chronic Myelogenous Leukemia (CML) Study - AUS09
A multi-center, open-label, exploratory research study for people suffering with CML in the chronic phase (CML-CP), who achieved a complete cytogenetic response (CCyR) while on an established therapy, but have a suboptimal molecular response.
Trial phase: Phase 2 Participation Duration: Participants will be taking the study drug daily for up to 5 years on this study. They will be required to return to the study doctor’s office at regular intervals so that their condition can be monitored and routine blood tests and safety evaluation can be carried out. Protocol Number: CAMN107AUS09 Chronic Myelogenous Leukemia (CML) - AUS17
The purpose of this study is to assess changes in chronic low-grade non-hematologic adverse events experienced by people with Philadelphia Chromosome positive (PH+) Chronic Myelogenous Leukemia in chronic phase when given a Novartis investigational drug after switching therapy. An “investigational drug” is a drug that is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 4 Participation Duration: Participation in this study will include 12 visits to your doctor's office/clinic or study center for about 1.5 years. Protocol Number: CAMN107AUS17 |